These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3799697)

  • 21. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of prazosin on serum lipids in patients with essential hypertension: a review of the findings presented at the Satellite Symposium on coronary heart disease: hypertension and other risk factors, Milan, 1983.
    Lowenstein J
    Am J Cardiol; 1984 Jan; 53(3):21A-23A. PubMed ID: 6141723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension.
    Davey MJ
    Am J Med; 1989 Aug; 87(2A):36S-44S. PubMed ID: 2569823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacotherapeutics of doxazosin.
    Taylor SH
    Am J Med; 1989 Aug; 87(2A):2S-11S. PubMed ID: 2569822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Forearm and finger hemodynamics, blood pressure control, and lipid changes in patients with diabetic hypertension treated with atenolol and prazosin.
    Kwan CM; Shepherd AM; Johnson J; Taylor WF
    Clin Pharmacol Ther; 1988 Aug; 44(2):202-10. PubMed ID: 3293875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.
    Fulton B; Wagstaff AJ; Sorkin EM
    Drugs; 1995 Feb; 49(2):295-320. PubMed ID: 7537194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-atherosclerotic and plasma lipid lowering effects of the novel calcium blocker with alpha 1-adrenoceptor antagonistic activity, monatepil, in high cholesterol diet-fed Japanese Macaca fuscata monkeys.
    Miyazaki M; Hosoki K; Okunishi H; Ishii K; Ikeno A; Okazaki Y
    Arzneimittelforschung; 1994 Mar; 44(3):288-97. PubMed ID: 8192692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of non-beta-blocking drugs on the lipid profile: are diuretics outclassed as initial therapy for hypertension?
    Ames RP
    Am Heart J; 1987 Oct; 114(4 Pt 2):998-1006. PubMed ID: 2889346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of hypotensive and hemodynamic effects of prazosin in patients with hypertension].
    Ostapiuk FE; Dobrotvorskaia TE; Samofanova MS; Shengeliia RG
    Kardiologiia; 1986 Mar; 26(3):45-9. PubMed ID: 3520086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects on lipid metabolism of antihypertensive drugs with alpha- and beta-adrenergic antagonist properties.
    Leren P
    Am J Med; 1987 Jan; 82(1A):31-5. PubMed ID: 2879461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of oral antihypertensive agents on blood lipid levels.
    Leren P
    Clin Ther; 1986; 8(3):309-19. PubMed ID: 2872961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension.
    Pool JL; Taylor AA; Nelson EB
    Am J Med; 1989 Aug; 87(2A):57S-61S. PubMed ID: 2569825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia.
    Superko HR; Wood PD; Krauss RM
    Am J Med; 1989 Jan; 86(1B):26-31. PubMed ID: 2913769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.